<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498770</url>
  </required_header>
  <id_info>
    <org_study_id>P08308</org_study_id>
    <secondary_id>MK-8274-108</secondary_id>
    <nct_id>NCT01498770</nct_id>
  </id_info>
  <brief_title>An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)</brief_title>
  <official_title>An Observational Drug Utilization Study of SYCREST^Â® (Asenapine) in the United Kingdom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to describe asenapine prescribing patterns in the United Kingdom (UK)
      during the post-approval period under conditions of usual practice. The use of asenapine in
      Bipolar Disorder and other indications will be described. To provide epidemiological and
      clinical perspective, use of aripiprazole and other comparator drugs will be described.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data source for this study will be the Clinical Practice Research Database (CPRD) in the
      UK. New users of asenapine during the period following the UK marketing launch of asenapine
      will be identified in the CPRD. Use in Bipolar Disorder and other indications, as well as
      baseline demographic and physical characteristics, including prior health status,
      comorbidities, concomitant medications and healthcare resource utilization, will be described
      for the asenapine cohort, for participants aged 18 or greater. Use of asenapine in the
      general practice setting among pediatric participants will be described.

      The primary comparison cohort will be aripiprazole. Participants in the aripiprazole cohort
      will be matched to participants treated with asenapine based on respective time after market
      entry. In addition, non-matched cohorts will be used to describe utilization of aripiprazole
      and other comparators.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2013</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">December 21, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and Proportion of Use, by Psychiatric Diagnosis, Among Asenapine and Aripiprazole Participants Aged 18 or Greater</measure>
    <time_frame>From baseline through 730 days after date of prescription</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Proportion of Use Among Asenapine and Aripiprazole Participants Aged 18 or Greater with Schizophrenia and No Diagnosis of Bipolar Disorder</measure>
    <time_frame>From baseline through 730 days after date of prescription</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Proportion of Use Among Asenapine and Aripiprazole Participants Aged 18 or Greater with No Diagnosis of Bipolar Disorder or Schizophrenia, by Other Diagnosis</measure>
    <time_frame>From baseline through 730 days after date of prescription</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Age of Asenapine Participants Aged 18 or Greater Initiating Asenapine During the First Year Since Drug Product Marketing in UK</measure>
    <time_frame>Baseline observation period (minimum of at least 365 days prior to date of prescription)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender of Asenapine Participants Aged 18 or Greater Initiating Asenapine During the First Year Since Drug Product Marketing in UK</measure>
    <time_frame>Baseline observation period (minimum of at least 365 days prior to date of prescription)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Proportion of Pediatric Use, by Psychiatric Diagnosis</measure>
    <time_frame>From baseline through 365 days after date of prescription</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Age of Asenapine Participants Less Than 18 Years Old Initiating Asenapine During the First Year Since Drug Product Marketing in UK</measure>
    <time_frame>Baseline observation period (minimum of at least 365 days prior to date of prescription)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender of Asenapine Participants Less Than 18 Years Old Initiating Asenapine During the First Year Since Drug Product Marketing in UK</measure>
    <time_frame>Baseline observation period (minimum of at least 365 days prior to date of prescription)</time_frame>
  </primary_outcome>
  <number_of_groups>13</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Asenapine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloperidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Paliperidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertindole</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotepine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>Asenapine prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Asenapine</arm_group_label>
    <other_name>Sycrest</other_name>
    <other_name>SCH 900274</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilfy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Ziprasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloperidone</intervention_name>
    <description>Iloperidone prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Iloperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Paliperidone prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Paliperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Lurasidone prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Lurasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Clozapine prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Clozapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Amisulpride prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertindole</intervention_name>
    <description>Sertindole prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Sertindole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zotepine</intervention_name>
    <description>Zotepine prescribed as recorded in the CPRD in the UK</description>
    <arm_group_label>Zotepine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is drawn from UK general practitioner practices participating in CPRD.
        The database is generally representative of the UK general population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Participants Treated with Asenapine:

          -  At least 1 prescription for asenapine within the study period

          -  Date of prescription occurs after the CPRD subject registration date or the database
             specific quality indicator date

          -  A minimum of 365 or more days of evaluable baseline observation time, occurring prior
             to the date of prescription for asenapine

        Inclusion Criteria for Participants Treated with a Comparator:

          -  Age 18 years or greater at the time participant receives a prescription for the
             comparator

          -  At least 1 prescription for either aripiprazole, quetiapine, risperidone, olanzapine,
             ziprasidone, iloperidone, paliperidone, lurasidone, clozapine, amisulpride, sertindole
             or zotepine within the study period

          -  Date of prescription occurs after the CPRD subject registration date or the database
             specific quality indicator date

          -  A minimum of 365 or more days of evaluable baseline observation time, occurring prior
             to the date of prescription for either aripiprazole, quetiapine, risperidone,
             olanzapine, ziprasidone, iloperidone, paliperidone, lurasidone, clozapine,
             amisulpride, sertindole or zotepine

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.encepp.eu/encepp/viewResource.htm?id=22678</url>
    <description>EU PAS Register (EUPAS17681)</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
    <mesh_term>Sertindole</mesh_term>
    <mesh_term>Zotepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

